Can I Take Caffeine With TB-500?

What Is TB-500, and Why Are Women Using It?

TB-500 is a synthetic analog of the active fragment (amino acids 17 to 23) of thymosin beta-4, a naturally occurring 43-amino-acid peptide found in high concentrations in platelets, wound fluid, and actin-sequestering tissue. Researchers and compounding pharmacies market it for tissue repair, inflammation reduction, and recovery from injury. It is not FDA-approved for any clinical indication, and it is available in the United States only through 503A compounding pharmacies on a patient-specific prescription basis.

Women are reaching for it largely through fitness and biohacking communities, where it is discussed for tendon healing, post-surgical recovery, and even connective-tissue conditions like hypermobility. Female-specific conditions that have drawn interest include endometriosis-related pelvic adhesion, post-cesarean recovery, and joint laxity during and after pregnancy. None of these uses has been evaluated in a randomized controlled trial in women.

What the Animal and In Vitro Data Show

The most frequently cited data come from rodent cardiac injury models. A 2012 study in the Journal of Molecular and Cellular Cardiology found that thymosin beta-4 administration reduced infarct size and promoted angiogenesis in mice with experimentally induced myocardial ischemia. A 2010 paper in Nature showed that thymosin beta-4 activated cardiac progenitor cells in adult mouse hearts. These are mouse studies. Extrapolating them to human tissue repair, let alone to the shorter 7-amino-acid active fragment marketed as TB-500, is a significant leap.

How Thymosin Beta-4 Relates to Female Physiology

Thymosin beta-4 is expressed in the endometrium and fluctuates across the menstrual cycle, with higher concentrations in the secretory phase. A 2004 paper in Fertility and Sterility documented endometrial thymosin beta-4 expression and suggested a role in implantation biology. Whether exogenous TB-500 supplementation alters endometrial receptivity is completely unknown. This is not a trivial gap for any woman who is trying to conceive.

How Caffeine Works in the Female Body

Caffeine is metabolized almost entirely by CYP1A2, a hepatic enzyme whose activity is strongly modulated by estrogen. Oral contraceptives reduce CYP1A2 activity by roughly 40 to 65%, meaning women on the pill or patch clear caffeine significantly more slowly than men or women not using hormonal contraception. A pharmacokinetic study in Clinical Pharmacology and Therapeutics confirmed that caffeine half-life extends from approximately 5 hours in ovulating women to more than 11 hours in women using combined oral contraceptives.

This is not a minor footnote. A woman who drinks two cups of coffee at 7 a.m. While on a combined pill may still have pharmacologically active caffeine circulating at bedtime.

The Perimenopause and Postmenopause Effect

Estrogen decline in perimenopause does not simply reverse the OCP-related slowdown. The picture is more complicated. As estrogen fluctuates and then falls, CYP1A2 activity becomes less predictable. Several perimenopausal women report heightened caffeine sensitivity, including palpitations, worsened hot flashes, and disrupted sleep. A 2014 study in Menopause found that caffeine intake was associated with more bothersome vasomotor symptoms in perimenopausal women, though the relationship was not causal.

Postmenopausal women using hormone therapy containing estrogen may again experience slower caffeine clearance compared with those not on HRT.

Caffeine and Blood Pressure in Women

Caffeine raises systolic blood pressure by approximately 3 to 15 mmHg acutely, an effect that is blunted in habitual users. A meta-analysis in the American Journal of Clinical Nutrition confirmed acute pressor effects with doses above 200 mg. Women with PCOS have a higher baseline prevalence of hypertension and endothelial dysfunction, making blood pressure monitoring more relevant in that group.

The TB-500 and Caffeine Interaction: What the Evidence Actually Shows

TB-500 itself is not metabolized by CYP1A2 or any other cytochrome P450 enzyme. As a short peptide, it is broken down by circulating proteases and excreted renally, following pharmacokinetics more similar to a biologic than a small-molecule drug. There is therefore no direct pharmacokinetic interaction between TB-500 and caffeine.

The interaction concern is pharmacodynamic: both compounds can influence overlapping physiological systems.

Blood Pressure and Cardiovascular Tone

Thymosin beta-4 promotes angiogenesis and has been shown in animal models to modulate nitric oxide production, which can affect vascular tone. A 2007 paper in Annals of the New York Academy of Sciences described thymosin beta-4's role in endothelial cell migration and nitric oxide signaling. Caffeine simultaneously exerts adenosine receptor antagonism, raising sympathetic tone and blood pressure. The combination of an agent that modulates vascular signaling with a stimulant that raises sympathetic tone is not well characterized in human trials.

For a woman who already has elevated blood pressure, PCOS-related cardiovascular risk, or is postmenopausal (when baseline cardiovascular risk rises), adding two compounds with cardiovascular effects without medical oversight is inadvisable.

Glucose and Metabolic Effects

Caffeine acutely impairs insulin sensitivity. A randomized crossover trial in Diabetes Care found that caffeine (250 mg) increased postprandial glucose by approximately 21% and reduced glucose disposal in habitual coffee drinkers with type 2 diabetes. Thymosin beta-4 has been linked in rodent models to effects on macrophage polarization and insulin signaling, though these findings are not yet replicated in humans. Women with PCOS, who have baseline insulin resistance in 65 to 80% of cases, are the subgroup for whom this overlap is most clinically relevant.

Inflammation and Immune Modulation

Thymosin beta-4's primary proposed mechanism in tissue repair is anti-inflammatory: it reduces TNF-alpha and IL-1beta signaling and promotes actin polymerization. Caffeine has mild anti-inflammatory effects at moderate doses through adenosine receptor modulation, but this effect is dose-dependent and inconsistent across studies. No published research has examined whether combining TB-500 with caffeine produces additive, antagonistic, or neutral effects on inflammatory markers in women.

The WomanRx Two-Pathway Framework for Assessing Peptide-Supplement Interactions

When no direct interaction data exists for a compounded peptide plus a supplement, clinicians at WomanRx evaluate two pathways:

1. Pharmacokinetic overlap: Does the supplement share metabolism, excretion, or protein binding with the peptide? For TB-500 plus caffeine: No. TB-500 is proteolytically cleaved; caffeine is CYP1A2-hepatic.
2. Pharmacodynamic overlap: Do both compounds act on the same downstream systems (cardiovascular tone, glucose handling, immune signaling)? For TB-500 plus caffeine: Yes. Both touch vascular biology and, to a lesser degree, glucose metabolism.

Under this framework, the combination is low-to-moderate concern, not high concern, but monitoring is still warranted.

Who This Combination May Be Right for (and Who Should Avoid It)

Women Who May Proceed With Monitoring

• Healthy, non-pregnant, non-lactating women aged 20 to 45 with normal blood pressure
• Women using TB-500 under direct prescriber supervision through a licensed 503A pharmacy
• Those who consume moderate caffeine (below 200 mg per day, roughly one to two standard cups of coffee)
• Women without PCOS, hypertension, or a personal history of cardiac arrhythmia

Women Who Should Use Caution or Avoid

• Women with PCOS: the combination of TB-500's unclear effect on insulin signaling and caffeine's known acute insulin resistance warrants a conversation with your endocrinologist or OB-GYN before starting.
• Perimenopausal and postmenopausal women with hypertension or on hormone therapy: your caffeine clearance is unpredictable, and cardiovascular baseline risk is higher.
• Women on combined oral contraceptives: caffeine half-life may already be extended; adding TB-500 without knowing your blood pressure trajectory is not risk-free.
• Women with a history of arrhythmia or structural heart disease: caffeine's pressor and chronotropic effects combined with a vascular-tone-modulating peptide deserve cardiology input.
• Women actively trying to conceive: the unknown effect of TB-500 on endometrial thymosin beta-4 expression makes this a hard stop. More on this below.

Pregnancy, Lactation, and Contraception

This section is required reading if there is any possibility you are pregnant, planning to conceive, or breastfeeding.

TB-500 in Pregnancy

TB-500 is contraindicated in pregnancy. No human pregnancy safety data exists. Because thymosin beta-4 plays a documented role in endometrial implantation biology and fetal tissue development, exogenous administration during organogenesis carries theoretical teratogenic risk that cannot be dismissed. The FDA has not assigned a pregnancy category to TB-500 because it holds no approved drug status, but any compounding prescriber applying standard precautionary principles would classify it as pregnancy-contraindicated based on mechanism alone.

If you are prescribed TB-500 by a compounding pharmacy and you are of reproductive age, your prescriber should discuss reliable contraception. If you become pregnant while using TB-500, stop the peptide immediately and contact your OB-GYN.

Caffeine in Pregnancy

ACOG Practice Bulletin guidance recommends limiting caffeine to fewer than 200 mg per day during pregnancy to reduce miscarriage and fetal growth restriction risk. A 2020 BMJ systematic review of 48 studies found no safe level of caffeine for pregnancy outcomes and suggested that even intakes below 200 mg/day were associated with adverse outcomes, though absolute risks remain small. The ACOG 200 mg threshold remains the clinical standard in the United States.

Lactation

TB-500 has no published human lactation data. Its molecular weight as a short peptide makes significant transfer into breast milk theoretically unlikely, but "theoretically unlikely" is not a safety clearance. The Drugs and Lactation Database (LactMed) at NIH contains no entry for thymosin beta-4 or its active fragment. Until data exists, the precautionary recommendation is to avoid TB-500 while breastfeeding.

Caffeine does transfer into breast milk, with infant dose estimated at approximately 0.06 to 1.5% of the maternal dose, a level considered low and generally compatible with breastfeeding at moderate maternal intake below 300 mg per day, per the American Academy of Pediatrics.

Dosing, Timing, and Practical Considerations

Typical TB-500 Dosing in Compounding Practice

Compounding protocols for TB-500 vary widely because no FDA-approved dosing standard exists. Commonly reported protocols use 2 to 2.5 mg subcutaneously two to three times per week for four to six weeks in a "loading phase," followed by a maintenance dose of 2 mg every two weeks. These numbers come from bodybuilding communities and small open-label veterinary use, not from human clinical trials. Your compounding prescriber should individualize the dose based on your weight, indication, and monitoring labs.

Does Timing Matter? Should You Separate Caffeine and TB-500?

Because the interaction is pharmacodynamic rather than pharmacokinetic, a simple dose-separation window will not eliminate the overlap in cardiovascular and metabolic effects. The more meaningful strategy is:

• Measure your resting blood pressure before starting TB-500 and recheck it at two and four weeks.
• Track your resting heart rate on injection days, noting whether caffeine timing correlates with palpitations.
• If you have PCOS or insulin resistance, consider checking fasting glucose and a two-hour postprandial glucose at baseline and at six weeks.
• Keep a caffeine diary for the first two weeks on TB-500. If you notice increased palpitations, anxiety, or blood pressure readings above 130/80 mmHg, reduce caffeine to below 100 mg per day and notify your prescriber.

What to Do If You Are Already Taking Both

If you are currently using both TB-500 and caffeine without problems, you are not in imminent danger. The overlap is moderate concern, not acute toxicity. Take a blood pressure reading now. If it is normal (below 120/80 mmHg) and you have no symptoms, continue with monitoring as described above. If it is elevated, bring this to your prescriber's attention before your next TB-500 dose.

The Evidence Gap: What Women Specifically Need to Know

Women have been systematically underrepresented in peptide and regenerative medicine research. The NIH's 2016 mandate requiring inclusion of female animals in preclinical research was a step forward, but most published TB-500 data predates this requirement and used male rodents. This means:

• Hormonal effects on TB-500 pharmacokinetics in women are unstudied.
• Whether the menstrual cycle phase at time of injection alters tissue distribution or effect is unknown.
• Whether TB-500 interacts with exogenous estrogen or progesterone in women using HRT or hormonal contraception is not characterized.

"The lack of female-specific data on peptide therapeutics is a genuine gap that affects clinical decision-making," said Dr. Maya Okafor, MD, WomanRx editorial board OB-GYN. "Until we have trials enrolling women at defined hormonal life stages, any prescribing in this space should include explicit monitoring and informed consent about what we simply do not know."

Monitoring Checklist for Women Using TB-500 With Caffeine

Use this checklist with your prescribing clinician before starting and at four to six weeks:

Before Starting

• Resting blood pressure (both arms if you have any cardiovascular history)
• Fasting glucose and fasting insulin if you have PCOS or metabolic syndrome
• Confirm pregnancy status (urine hCG) if you are of reproductive age
• Document current caffeine intake in mg per day

At 4 to 6 Weeks

• Repeat blood pressure
• Note any new palpitations, chest tightness, headache, or anxiety
• Repeat fasting glucose if baseline was abnormal
• Report injection-site reactions to your prescribing pharmacist and prescriber

Conditions and Life Stages Where This Combination Deserves Extra Attention

PCOS

Women with PCOS already carry elevated cardiovascular and metabolic risk. PCOS affects an estimated 6 to 12% of reproductive-age women in the United States, and insulin resistance is present in the majority. Adding a compound with unknown metabolic effects (TB-500) to a stimulant with confirmed acute insulin-sensitizing interference (caffeine at high doses) requires metabolic monitoring, not just symptom tracking.

Perimenopause

Hormonal flux in perimenopause makes caffeine pharmacokinetics less predictable, and cardiovascular risk begins to climb. Women in this stage should start with the lowest caffeine intake they can tolerate and avoid caffeine in the four to six hours before a TB-500 injection if they experience cardiovascular symptoms.

Postmenopause

Postmenopausal women who are not on hormone therapy tend to have lower estrogen, which may actually improve caffeine clearance slightly compared to premenopausal women on hormonal contraception. Still, baseline cardiovascular risk is higher in this group, and any new compound that touches vascular biology deserves blood pressure monitoring.

Trying to Conceive

Stop TB-500. Full stop. The endometrial biology concern described earlier, combined with zero human safety data in preconception, makes this a firm recommendation. Caffeine should be brought below 200 mg per day as you transition to an active conception attempt, per ACOG.